XprESS ET Registry
- Conditions
- Eustachian Tube Dysfunction
- Registration Number
- NCT04136977
- Lead Sponsor
- Entellus Medical, Inc.
- Brief Summary
A prospective, multicenter, registry of patients undergoing balloon dilation of the Eustachian tubes (ET).
- Detailed Description
This is a prospective, multicenter, single-arm, postmarket registry enrolling up to 300 participants who are planning to undergo balloon dilation of the Eustachian tubes for treatment of chronic/persistent Eustachian tube dysfunction (ETD). Procedural information will be collect as well as efficacy and safety data through 6 months post procedure.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 169
- Be at least 18 years old
- Have been diagnosed with persistent/chronic Eustachian tube dysfunction (duration 3 months or more)
- Be a candidate for unilateral or bilateral Eustachian tube balloon dilation using the XprESS device
- Be able to read and understand English
- Be willing and able to provide informed consent
- Be willing to comply with the protocol requirements
- Have a history of patulous Eustachian tube
- Require additional ear surgery (eg, myringotomy, tympanostomy) at the time of study procedure
- Have evidence of internal carotid artery dehiscence
- Be currently participating in any other drug or device clinical studies, excluding postapproval or marketing registry studies
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complication rate 6 Months Percentage of participants who experience 1 or more serious adverse events that are related to the device and/or procedure.
Change in mean Eustachian Tube Dysfunction Questionnaire (ETDQ-7) score 6 Months Change from baseline to follow-up in the mean overall ETDQ-7 score. The ETDQ-7 is a validated 7-item patient-reported questionnaire reporting the presence and severity of symptoms associated with Eustachian tube dysfunction. Each item is scored from 1 (normal) to 7 (severe). The overall score is the mean score of the 7 items.
- Secondary Outcome Measures
Name Time Method Procedural information Procedure through 6-week follow-up Details of the balloon dilation procedure, including setting, anesthesia, technical success, concomitant procedures, procedure/device-related adverse events, and recovery time.
Improvement in ability to perform a Valsalva maneuver 6 Months Percentage of participants unable to perform the Valsalva maneuver (negative) at baseline who are able to perform the maneuver (positive) at follow-up.
Minimal clinically important difference in ETDQ-7 score 6 Months Percentage of participants achieving the minimal clinical important difference in overall ETDQ-7 score (reduction from baseline of 0.5 points or more). The ETDQ-7 is a validated 7-item patient-reported questionnaire reporting the presence and severity of symptoms associated with Eustachian tube dysfunction. Each item is scored from 1 (normal) to 7 (severe). The overall score is the mean score of the 7 items.
Participant satisfaction: Proportion of participants indicating satisfaction and willing to recommend the procedure to friends or family 6 Months Percentage of participants indicating satisfaction and willing to recommend the procedure to friends or family.
Change in work productivity/activity impairment 6 Months Participants complete the validated Work Productivity and Activity Impairment (WPAI) at baseline and 6 month follow-up. The questionnaire consists of 6 questions that evaluate absenteeism, presenteeism, work productivity loss, and activity impairment over the previous week. Results are expressed as the percentage of impairment from 0 to 100, for which higher numbers indicate worse outcomes (ie, greater impairment and less productivity). Absenteeism is calculated by dividing the number of hours missed by the sum of the numbers of hours missed plus the number of hours worked. Presenteeism, is calculated by dividing the response to productivity at work question by 10, while activity impairment is calculated by dividing the response to the ability to carry out daily activities question by 10. Finally, the overall work impairment/productivity loss is calculated as the sum of absenteeism and the product of presenteeism and time at work.
Change from baseline in chronic rhinosinusitis symptoms 6 Months Participants will complete the validated 22-item SinoNasal Outcomes Test (SNOT-22) to evaluate change in chronic rhinosinusitis symptoms. Each of the 22 symptoms on the questionnaire are rated by the participant from 0 (no problem) to 5 (bad). A sum of the 22 item scores provides the overall score, which can range from 0 to 110.
Revision Eustachian tube dilation 6 Months Percentage of participants who require revision dilation on an ear that was treated in the initial procedure.
Surgical interventions 6 Months Percentage of participants requiring surgical ear intervention (other than balloon dilation) on an ear that was treated in the initial procedure but has recurrent or continuing ETD symptoms.
Improvement in tympanogram 6 Months Percentage of participants with an abnormal tympanogram (type B or C) at baseline who have a normal (type A) or improved (type B to type C) tympanogram at follow-up.
Improvement in tympanic membrane position 6 Months Percentage of participants with a retracted tympanic membrane at baseline who have a normal tympanic membrane position at follow-up.
Trial Locations
- Locations (11)
Breathe Clear Institute
🇺🇸Torrance, California, United States
Lakeside ENT
🇺🇸Canandaigua, New York, United States
Augusta ENT and Allergy
🇺🇸Evans, Georgia, United States
ENT Consultants of Nevada
🇺🇸Las Vegas, Nevada, United States
St. Vincent Anderson Hospital
🇺🇸Anderson, Indiana, United States
Colorado ENT and Allergy
🇺🇸Colorado Springs, Colorado, United States
Ear Nose and Throat Consultants
🇺🇸Southfield, Michigan, United States
St Cloud ENT
🇺🇸Saint Cloud, Minnesota, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
National Allergy and ENT
🇺🇸Charleston, South Carolina, United States